AntriaBio
Home
About
Corporate Presentation
Leadership
Board of Directors
Scientific Advisory Board
Pipeline
Overview
RZ358
RZ402
Clinical Trials
Publications
News
Press Releases
Media
IR Calendar
Publications
Investors
Overview
IR Overview
News / Events
Press Releases
IR Calendar
Corporate Presentation
Publications
Email Alerts
Company Information
Management Team
IR Contacts
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Analyst Coverage
Analyst Coverage
Corporate Governance
Board of Directors
Corporate Governance Documents
Careers
Contact
Press Releases
Home
Investors
News / Events
Press Releases
Investors
Overview
News / Events
Press Releases
IR Calendar
Corporate Presentation
Publications
Email Alerts
Company Information
Stock Data
SEC Filings
Analyst Coverage
Corporate Governance
Press Releases
Search
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
Jan 12, 2021
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
